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Abstract 19 
This study describes the initial testing of a novel strategy for neutralisation of lentiviruses using 20 
the fundamental biology of enveloped viruses’ assembly and budding. In the field of gene 21 
therapy, viral vector surface proteins have been manipulated in order to redirect host cell 22 
specificity by alteration of pseudo-types.  We tested whether known viral pseudo-typing proteins 23 
or surface proteins known to be recruited to the HIV envelope could be engineered to carry 24 
neutralising epitopes from another microorganism onto the lentiviral surface.  Our results identify 25 
ICAM1 as a novel vehicle for lentiviral pseudo-typing. Importantly, we show that in a model 26 
lentiviral system ICAM1 can be engineered in chimeric form to result in expression of a fragment 27 
of the Tetanus toxoid on the viral membrane and that these viruses can then be neutralised by 28 
human serum antibodies protective against Tetanus.  This raises the possibility of delivering 29 
chimeric antigens as a gene therapy in HIV infected patients.  30 
3 
Introduction 31 
In 2015 UNAIDS estimated that 36.9 million people were living with HIV infection and that there 32 
were 1.2 million AIDS related deaths 33 
http://www.unaids.org/sites/default/files/media_asset/20150901_FactSheet_2015_en.pdf).  34 
Much is being learned from recent clinical trials but efforts to find either a vaccine or a cure have 35 
been so far unsuccessful 1-3.  This leaves infected individuals facing a possible lifetime on anti-36 
retroviral drug regimes, which though revolutionary are challenging and costly to implement and 37 
are not without side-effects 4, 5.  HIV biology presents many challenges to medical advances 38 
including its rapid systemic spread from site of entry, the massive antigenic diversity generated 39 
by its mode of replication and the damage it causes to the immune system.  Furthermore, HIV 40 
latency, though incompletely understood, has been demonstrated to be a source of viral re-41 
emergence upon cessation of drug therapy and of drug resistant strains of HIV 6-8. 42 
In this paper we would like to propose a novel strategy to circumvent the ability of HIV to 43 
evade immune clearance and present data using lentiviral models that support initial proof of 44 
concept; we call this strategy Trojan Insertion.  HIV infection is characterised by continual cycles 45 
of immune evasion due to the rapid selection of escape mutations 9-12.  Our strategy involves 46 
forcing HIV virions to express on their surface immunogens from other pathogens, to which there 47 
is a pre-existing memory response which can rapidly and decisively clear the emerging virus. 48 
Lentiviruses like HIV are enveloped by the host-cell plasma membrane, which coats the 49 
virus as it buds from the cell.  Some host cell plasma membrane proteins may be actively 50 
recruited to sites of HIV budding and can increase infectivity 13, 14. This might be exploited if host 51 
cells can be made to express immunogens on their surface in a form that can be incorporated 52 
onto budding virions.  To this end we have designed chimeric proteins, which we call Trojans, 53 
4 
which consist of a transmembrane domain from proteins known to be incorporated into lentiviral 54 
envelope membranes artificially fused to an immunogenic extracellular domain. 55 
The extracellular antigen selected for our model experiments was the Tetanus Fragment 56 
C (TetFrC) antigen.  Tetanus Toxoid has been historically used with great success for 57 
immunisation of humans against Clostridium Tetani.  The serum of immunised humans has been 58 
shown to contain anti-toxoid neutralising antibodies that can be administered as a passive 59 
therapy against tetanus infection 15. In addition, a modified fragment of the Tetanus Toxin has 60 
been shown to be an effective adjuvant fusion molecule to stimulate T cell responses against 61 
human cancers 16, 17. 62 
We decided to test two potential membrane anchors for fusion to the TetFrC extracellular 63 
domain.  The first is the Vesicular Stomatitis Virus glycoprotein (VSVg). This is a virus 64 
attachment and fusion protein, which confers viral tropism for a wide variety of cell types and 65 
has been shown to be successfully incorporated into the surface membrane of lentiviral vectors 66 
18, 19.  These properties have been successfully utilised for pseudo-typing many recombinant 67 
lentiviral vectors.  This protein has been genetically engineered to bear the 52 kDa protein 68 
Streptavidin in place of its native attachment and fusogenic extracellular domains. Kaikkonen et 69 
al. showed that virions expressing Streptavidin in this way on their membrane could be targeted 70 
to a particular cell type using bridging biotinylated antibodies against cell type-specific markers 71 
20. 72 
The second transmembrane anchor is derived from ICAM1.  This protein has been shown 73 
to be recruited to the HIV surface via a direct interaction with the HIV protein gag and as a result 74 
may be present at relatively high levels on free virions 13, 21.  ICAM1 has been extensively studied 75 
5 
and the exonic sequences contributing to its transmembrane and cytoplasmic domains are well-76 
defined. 77 
Having designed our chimeric Trojan proteins we set out to test whether they can be used 78 
to coat lentiviral vectors and whether viruses so coated can be neutralised by a simulated human 79 
immune response.  Our data show that the Trojan proteins can transferred by human lentiviral 80 
vector packaging and T-cell lines both transiently and stably.  Furthermore, we show that 81 
lentiviral vectors packaged in the presence of Trojan proteins are measurably infectious and this 82 
infectivity can be neutralised by human anti-tetanus serum antibodies. 83 
  84 
  85 
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Materials and Methods 86 
Chimeric Constructs 87 
Chimeric cDNA constructs TV, TI, SV and SI (Figure 1) were designed with a four domain 88 
structure consisting of a signal peptide, sequences encoding a 5’ FLAG® epitope tag (Sigma 89 
Aldrich), an extracellular domain, and finally a transmembrane/cytoplasmic domain to direct 90 
plasma membrane. The signal peptides were either from the baculovirus Gp64 protein 91 
(constructs TV and SV) or from human ICAM1 (constructs TI and SI). 92 
TetFrC sequence was provided by J. Rice (Southampton University UK) 16, 22.  Sequences 93 
for gp64 signal peptide, VSVg transmembrane and cytoplasmic domain were provided by M. 94 
Kaikkonen (University of Kuopio, Finland) 20.  ICAM1 signal and transmembrane and cytoplasmic 95 
domain sequences were identified from published sequences 23 and NCBI entry CCDS12231.1. 96 
Chimeric cDNA constructs were produced by GeneArt® (Life Technologies). Chimeric 97 
cDNA constructs TV and TI were subcloned using EcoRV and NheI restriction enzymes (New 98 
England Biolabs, UK) to the pRRLsc_C_W self-inactivating integrating lentiviral vector plasmid 99 
with a central polypurine tract/central termination sequence.  This vector encodes a lentiviral 100 
transfer cassette with expression driven from an hCMV promoter with a Woodchuck hepatitis 101 
virus posttranscriptional regulatory element. Resulting plasmids were designated as TV and TI 102 
respectively and were subjected to Sanger sequencing to confirm chimeric gene sequences.  To 103 
create an enhanced green fluorescent protein (eGFP)-expressing control virus (LVGFP), the 104 
pRRLsc_CEW transfer plasmid was used and has been previously described 24. 105 
Streptavidin cDNA was recovered by FLAG® tag primer extension proof-reading PCR 106 
amplification of Streptavidin sequences from plasmid pCMV-SA-VSV-GED (provided by M. 107 
Kaikkonen, University of Kuopio, Finland) with first round primers forward 108 
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CAAGGACGATGACGACAAGGACCCCTCCAAGGAC and reverse 109 
ATCCCGGGCTGCTGAACGGCGTCGAG and for second round amplification forward primer 110 
ATAGGATCCATGGACTACAAGGACGATGACGACAAG.  PCR products were digested with 111 
XmaI and BamHI and subcloned into plasmids TV and TI using BamHI and AgeI enzyme sites 112 
to create SV and SI, respectively.  Sanger sequencing was used to confirm chimeric gene 113 
sequences. 114 
Cell lines and Culture 115 
Human Embryonic Kidney (HEK) 293T and human fibrosarcoma HT-1080 cell lines were 116 
obtained from ATCC.  PM1 T-cell line was obtained from National Institute for Biological 117 
Standards and Control (UK).  All cell lines were cultured in High Glucose (4.5 g/L) Dulbecco’s 118 
Modified Eagle’s Medium (DMEM) (PAA, UK), with stable Glutamine.  Unless otherwise 119 
indicated medium was supplemented with 10 % foetal bovine serum (FBS) (Gibco, UK), 100 120 
IU/mL penicillin, and 100 µg/mL streptomycin (Gibco, UK) 121 
Transient expression of chimeric constructs 122 
1x106 HEK 293T cells were grown for 24 h. Cells were then transfected with 5 µg lentiviral 123 
transfer expression cassette plasmids (TV, TI, SV and SI) using Lipofectamine® (Life 124 
Technologies) according to manufacturer’s instructions.  On day 1 post-transfection cells were 125 
removed from flasks using Trypsin EDTA (Gibco UK), washed and returned to new flasks with 126 
fresh media.  On day 3 post-transfection cells were harvested using 0.5 mM EDTA in PBS 127 
(Sigma Aldrich) and stained with either 5 µg/mL of mouse M2 anti-FLAG® antibody (Sigma 128 
Aldrich) or neat mouse anti-TetFrC hybridoma supernatant 31e11 (kindly provided by C. Watts, 129 
University of Dundee UK).  Negative control cells, mock transfected in the absence of plasmid, 130 
were stained with 5 µg/mL isotype control antibody mouse IgG1.  The secondary antibody in 131 
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each case was goat anti-mouse Alexa Fluor®647 (GaM647, Life Technologies).  After staining 132 
cells were fixed with 2 % paraformaldehyde and singlet cells analysed by flow cytometry using 133 
a FACS Canto II machine (Becton Dickinson).  FACS Plots and associated measurements were 134 
generated using FlowJo software version 8.8.6 (Treestar Inc.). 135 
For further quantitation of chimeric protein expression, 0.2x106 293T cells were transfected 136 
24h post-plating with 1.6 g of transfer cassette plasmid using Calcium Phosphate which was to 137 
be used in lentiviral packaging. Gene expression was detected at 48h by antibody staining as 138 
described above.  Statistical analysis was performed using GraphPad Prism 6 statistical software 139 
(GraphPadSoftware, San Diego, CA).  The levels of gene expression were compared by 140 
Ordinary One-way ANOVA with Tukey’s post-hoc test for multiple comparisons. 141 
Lentiviral Vector Production 142 
Lentiviral vectors were produced by calcium phosphate mediated transfection into HEK-293T 143 
cells, using VSVg pseudotype for all vectors.  Plasmids used for lentiviral production are as 144 
previously described 25. Cells were transiently transfected with 12.5 µg packaging plasmid 145 
(pMDLg/pRRE), 6.25 µg pRSV-REV, 7 µg pMD2.VSV-G and 25 µg of transfer plasmid.   146 
Viruses were titrated for Transducing Units/mL by transduction with limiting dilutions and 147 
FACS as previously described 25, using the HT1080 cell line. Cytoplasmic eGFP gene 148 
expression in singlet cell populations was measured directly in the FITC channel. Surface 149 
chimeric Trojan protein expression was detected by binding of the M2 anti-FLAG® antibody 150 
(Sigma) as described above. Percentage cells expressing surface FLAG® epitope above 151 
background detected in mock transduced cells was measured in the APC channel.  Mean titres 152 
for each lentiviral vector were compared by Ordinary One-way ANOVA with Tukey’s post-hoc 153 
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test for multiple comparisons using GraphPad Prism 6 statistical software (GraphPadSoftware, 154 
San Diego, CA). 155 
Lentiviral transduction 156 
For testing of production of chimeric proteins in cell lines, 5 x 105 cells were transduced at 157 
multiplicity of infection (MOI) of 1 in DMEM 10 % FCS in the presence of 8 µg/mL polybrene 158 
(Sigma).  On day 3 post-infection half the cells were analysed for surface FLAG® expression by 159 
antibody staining and FACS as described above.  Remaining cells were subjected to clonal 160 
dilution (3 cells per mL) and distributed at 200 µL per well to 96-well round bottom plates. Wells 161 
containing growing colonies were expanded until enough cells were available to be sampled for 162 
surface FLAG® epitope expression by M2 antibody binding and FACS as described above. 163 
Immunoprecipitation and Western Blotting 164 
Lentiviral suspensions were prepared as described above.  As a positive control for 165 
immunoprecipitation cell lysates were prepared from 293T cells transiently transfected with TI 166 
and 24 (as described above). Cells were lysed at 50 x106 cells/mL in ONYX buffer (20 mM Tris 167 
(pH 7.4), 140 mM NaCl, 1 mM EGTA, 1 % Triton, 10 % glycerol, 50 mM iodoacetamide and 168 
protease inhibitor cocktail (Roche) according to standard methods. 169 
Protein concentration of viral preparations and cell lysates was analysed using the Micro 170 
BCA kit (Perbio) according to manufacturer’s instructions. 10 µg of protein from each sample 171 
was subjected to immunoprecipitation as previously described 26 using human anti-tetanus 172 
polyclonal serum IgGs (NIBSC reference antibody TE-3) or Isotype human polyclonal IgGs 173 
(Sigma). Recovered beads were washed and treated with PNGase F (New England Biolabs).  174 
Immunoprecipitated proteins were released from beads during denaturation as described by 175 
manufacturer into LDS sample buffer (Life Technologies) with addition of 50 µM DTT (Sigma). 176 
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After SDS-PAGE and blotting, PVDF membranes were probed with HRP-conjugated M2 177 
anti-FLAG® antibody (Sigma), followed by chemiluminescent detection using ECLTM reagent (GE 178 
Healthcare). As an additional control 1 µg of each lentiviral preparation was left unprecipitated, 179 
denatured, treated with PNGase F and then subjected to SDS-PAGE and western blotting as for 180 
the immunoprecipitated proteins. 181 
Neutralisation assay 182 
6.5x105 transducing units of vector was pretreated in 100 µL PBS for 30 min with 100 µg of 183 
human anti-Tetanus polyclonal IgG antibody (NIBSC, described above), or with 100 µg of human 184 
IgG (hIgG) isotype control antibody (Sigma). 105 HT1080 cells were then transduced in standard 185 
growth medium for 18 h before vector was removed and cells washed with PBS to remove any 186 
unbound antibody or viral vector 48 h post-infection cells were fixed with 2 % paraformaldehyde 187 
and analysed by FACS for expression of the relevant transfer cassette as described above. 188 
Mean percentage gene expression-positive cells above background (from mock-189 
transduced cells) was calculated.  Mean gene expression resulting from successful 190 
transductions was calculated from a minimum of 3 transduced wells for each combination of 191 
virus and antibodies.  Error bars were calculated as ± Standard Deviation (SD) of the mean.  192 
Statistical analysis was performed using GraphPad Prism 6 statistical software 193 
(GraphPadSoftware, San Diego, CA).  The effects of the different treatments on transgene gene 194 
expression as a proxy for virus infectivity were compared using a One-way ANOVA with Sidak's 195 
multiple comparisons post-hoc test comparing the percentage transduction by each treated 196 
vector with the corresponding PBS treated vector control.  197 
 198 
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Results 200 
Transient expression of chimeric constructs results in surface-membrane protein 201 
expression 202 
In order to be incorporated into the lentiviral membrane chimeric proteins must first be 203 
incorporated into the host cell membrane.  Since we planned to use 293T cells as packaging 204 
cells for lentiviral vector production, we wanted to first demonstrate that our novel chimeric 205 
proteins could be expressed from our lentiviral transfer expression cassette plasmids onto the 206 
surface plasma membrane of these cells. 207 
Initially, we wanted to test whether we could use commercially produced and well-208 
characterised M2 anti-FLAG® antibody staining as a marker for TetFrC-chimeric protein 209 
expression. To this end, 293T cells were transiently transfected with plasmids TV, TI, SV or SI, 210 
harbouring FLAG®-tagged TetFrC or streptavidin chimeric protein genes, using Lipofectamine®.  211 
On day 3 after transfection cells were harvested and analysed for chimeric protein expression 212 
(Figure 2a) by FACS analysis of surface binding of the anti-FLAG® epitope antibody M2 (black 213 
line plot), or of anti-Tetanus Fragment C hybridoma supernatant 14e11 (dashed line plot).  As a 214 
negative control a sample of each transfectant was stained with an isotype control mouse IgG 215 
primary antibody (grey-filled plot). 216 
In TV and TI transfections, surface expression of chimeric proteins was detectable using 217 
anti-FLAG® epitope antibody M2 in parallel to 14e11 anti-tetanus hybridoma supernatant.  We 218 
therefore used M2 anti-FLAG® antibody staining as a marker for TetFrC expression in 219 
subsequent experiments. 220 
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In SV and SI transfections surface expression of chimeric proteins was also detectable 221 
using anti-FLAG® epitope antibody M2.  As expected, the anti-tetanus hybridoma supernatant 222 
did not bind to the Streptavidin extracellular domain-bearing chimeric proteins. 223 
In addition, samples of transfected cells were harvested with trypsin/EDTA instead of EDTA 224 
alone, and also with and without fixation to make sure that no epitopes to be detected in later 225 
experiments were trypsin or paraformaldehyde sensitive.  There was no evidence for a decrease 226 
in either anti-TetFrC or anti-FLAG® epitope antibody binding with either of these treatments (data 227 
not shown). 228 
To further quantify surface expression levels of each chimeric protein, 293T cells were 229 
transiently transfected with transfer plasmids using Calcium Phosphate, which is used in 230 
lentiviral packaging, and analysed for surface expression of chimeric proteins.  Plots from 231 
representative wells are shown in Figure 2b.  The percentage positive cells above background 232 
and median fluorescence intensities (MFIs) were measured for all wells and Figure 2c shows 233 
mean+/-SD for each measurement in independent transfections. 234 
The TetFrC-VSVg chimeric plasmid (TV) produced a population of cells with mean 48±3 % 235 
surface FLAG® expression, which were detected with a MFI of 714±20 (Figure 2c). For the 236 
TetFrC-ICAM1 chimera (TI) a mean of 77±3 % of cells demonstrating anti-FLAG® staining above 237 
background was observed, and with a MFI of 1306±79 for this population.  In the case of the 238 
matched Streptavidin control chimeras (Streptavidin-VSVg, SV and Streptavidin-ICAM1, SI) 239 
cells transfected with APGSV were 60±3 % FLAG® positive with a MFI of 854±50 and 293T cells 240 
transfected with SI showed 71±9 % surface FLAG®-positive cells and a MFI of 1317±468. 241 
Statistical analysis showed that transient transfection with TV (TetFrC-VSVg) resulted in 242 
significantly lower mean percentage of FLAG®-positive cells than TI and SI but not SV; the 243 
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greatest significance was seen when comparing transient transfectants of TetFrC-VSVg (TV) 244 
with TetFrC-ICAM1 (TI).  In addition, SV (Streptavidin-VSVg) transfectants had significantly 245 
lower percentage FLAG®-positive cells compared to TI (TetFrC-ICAM1) transfected cells.  MFI 246 
comparison did not result in any significant difference between the 4 different chimeric proteins 247 
on the surface of positive cells. These results showed that, with some variation, each chimera 248 
could be expected to be expressed on the surface of the cell line to be used for lentiviral vector 249 
packaging. 250 
Lentiviral transfer cassettes bearing chimeric constructs can be incorporated into 251 
infectious lentiviral vector particles but with variable titres 252 
In order to be able to detect whether lentiviral vectors could incorporate TetFrC chimeras and 253 
thus be susceptible to neutralisation with anti-TetFrC antibodies, we first needed to test whether 254 
transfer cassette expression in transduced cells could be used to measure infectivity.  Transfer 255 
plasmids TV, TI, SV and SI were therefore co-transfected to 293T cells with lentiviral packaging 256 
plasmids to create VSVg-pseudotyped lentiviral vectors LVTV, LVTI, LVSV and LVSI 257 
respectively. On day 2 post-transfection supernatants were harvested and ultra-centrifuged to 258 
recover lentiviral particles.  Lentiviral preparations were then titrated by transduction of HT1080 259 
fibrosarcoma cells and measurement of transfer cassette expression through binding of anti-260 
FLAG® antibody.  At least 3 separate lentiviral preparations were produced for each virus and 261 
putative chimera-bearing viruses were prepared alongside a well characterised, lentiviral vector 262 
expressing cytoplasmic eGFP protein, as a positive control for virus manufacture.  263 
The titres (Transducing Units/mL) produced for each virus are shown in Table 1. Transfer 264 
plasmids bearing chimeric constructs TV, TI, SV and SI were shown to be packaged into lentiviral 265 
particles and detection of chimeric protein expression on target cells through detection of the 266 
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FLAG® epitope could then be used to detect infectivity of lentiviral preparations. Variation in 267 
mean titres for viruses LVGFP, LVTV, LVTI and LVSI did not reach statistical significance.   268 
However, for LVSV (Streptavidin-ICAM1) the trend was for lower titres with one batch producing 269 
no detectable titre.  Therefore, we proceeded by focusing on the LVTI (TetFrC-ICAM1) and 270 
negative control LVSI (Streptavidin-ICAM1) pair. 271 
Chimeric proteins can be stably expressed on HEK293T cells and PM1 T-cells 272 
The lentiviral packaging system used in each virus was integration competent, which means that 273 
the transfer expression cassette could spontaneously integrate into the host genome of 274 
transduced cells 27.  Therefore we decided to test whether the chimeric constructs could be 275 
transferred by infection and stably expressed on human cell lines and, in particular, on a human 276 
T-cell line. 277 
 We had already shown that the chimeric proteins were transiently expressed on HEK 278 
293T cells, so we transduced 293T cells with LVTI and LVSI as a control.  In addition, we 279 
transduced the human T cell line PM1 which is a CD4+CXCR5+ T cell line. The two cell lines 280 
were transduced with an MOI of 1 of viruses LVTI (encoding TetFrC-ICAM1) and LVSI (encoding 281 
Streptavidin-ICAM1).  On day 3 post-infection a sample of cells transduced with each virus was 282 
analysed for surface chimera expression (Figure 3a and b).  For 293T cells transduced with LVTI 283 
(Figure 3a left) 98 % cells were positive for surface FLAG® expression while 59 % were positive 284 
in cells transduced with LVSI (Figure 3b right).  For PM1 cells transduced with the same viruses 285 
LVTI infection resulted in 67 % FLAG®-positive cells and LVSI infection produced 14 % positive 286 
cells.  Attempts to infect PM1 cells with higher MOIs produced cell toxicity (data not shown) and 287 
did not increase expression levels.   288 
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In order to analyse stable chimeric protein expression on populations derived from single 289 
parent cells, cells from the infections described above were diluted to give on average less than 290 
one cell seeded per well in 96 well plates.  Growing colonies were allowed to expand until enough 291 
cells were available for staining with anti-FLAG® antibody and FACS analysis; 12-15 colonies 292 
for each cell line and infection were analysed from d23 post transduction. For 293T cells there 293 
were 6 positive colonies for LVTI infection and 3 for LVSI infection.  For PM1 there were 4 294 
positive colonies with LVTI infection and one with LVSI infection. 295 
For each cell line the highest expressing colony (by percentage FLAG®-positive cells above 296 
background) for each infection was passaged until 6 weeks post-infection and analysed by FACS 297 
for transgene expression (figure 3c and d).  The LVTI TetFrC-ICAM1 chimeric transgene was 298 
expressed on 98 % of cells above background on colony 293T TI.9 but with a broad range of 299 
Fluorescence Intensity (Figure 3c left). The LVSI Streptavidin-ICAM1 control chimeric transgene 300 
on colony 293T SI.9 was also expressed with a broad range of fluorescence intensity and on 90 301 
% of cells above background (Figure 3c right).  302 
For the selected PM1 colonies the percentage of cells expressing the transgenes were 56 303 
% (PM1 colony TI.20, Figure 3d left) and 63 % (PM1 colony SI.6). Each colony had a discrete 304 
peak of higher expressing cells with the MFI of the peak for TetFrC-ICAM1 expression measured 305 
at 700 and for Streptavidin-ICAM1 at 414.  There were also dim and negative cells within each 306 
colony, which may represent cells that have downregulated or lost the transgenes.  Overall the 307 
results show that our Trojan construct can be transferred to human T cell lines by infection and 308 
expression of the transgenes can be maintained over a 6 week period. 309 
 310 
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Chimeric proteins in lentiviral preparations can be recognised by immune human anti-311 
Tetanus sera 312 
We have shown that lentiviral vector can be used to confer surface membrane expression of 313 
chimeric proteins to target cells. In order to initially investigate whether FLAG®-TetFrC chimeric 314 
proteins could be detected by TetFrC specific antibodies in lentiviral preparations, an 315 
immunoprecipitation experiment was performed (Figure 4). 316 
 As a control for the starting sample equal amounts of protein from each vector were left 317 
unprecipitated but otherwise treated as for the immunoprecipitates (lane 1).  As a positive control 318 
for immunoprecipitation, 293T cells were transiently transfected with each lentiviral chimeric 319 
expression vector (data not shown but expression of chimeric proteins demonstrated as for 320 
Figure 1) and lysed.  Lysates were immunoprecipitated with Protein G-sepharose beads to which 321 
negative isotype control polyclonal human IgGs (lane 2) or polyclonal human immune serum 322 
anti-tetanus IgGs (lane 3) were stably cross-linked.  In parallel, equal amounts of protein from 323 
LVTI and SI preparations were incubated with the same beads, namely Protein G-sepharose 324 
beads conjugated with either human IgGs (lane 4) or human immune serum anti-tetanus IgGs 325 
(lane 5).  Proteins bound by the antibody-conjugated beads were subject to SDS-PAGE and 326 
western blotting with M2-HRP conjugated antibody probe to detect the FLAG®-epitope. 327 
Molecular weight prediction from primary amino acid sequences gave expected average 328 
masses of 60 kDa for FLAG®-TetFrC-ICAM1 (LVTI) and 27 kDa for FLAG®-Streptavidin-ICAM1 329 
(LVSI) (Expasy Compute pI/MW).  In each unprecipitated lentiviral preparation, a band of 330 
consistent molecular weight with the appropriate chimeric construct was detected by anti-FLAG® 331 
antibody showing that each lentiviral vector preparation contained FLAG®-tagged proteins 332 
consistent in molecular weight with those predicted for the chimeric constructs.  When lysates 333 
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from transfected cells known to be expressing the chimeras were immunoprecipitated with anti-334 
tetanus antibodies from human sera, bands of expected molecular weight were also detected by 335 
M2 antibody probe that were not seen in the isotype control lanes. 336 
Finally, when lentiviral preparations themselves were immunoprecipitated, FLAG proteins 337 
of the predicted molecular weights for the chimeric constructs were specifically pulled down with 338 
human anti-tetanus antibodies but not with isotype control antibodies.  These results showed 339 
that the chimeric proteins are capable of being specifically bound by human anti-tetanus 340 
antibodies and that chimeric proteins are detectable in lentiviral preparations. 341 
Lentiviral vectors with envelope associated chimeric proteins are susceptible to 342 
neutralisation with anti-tetanus antibodies 343 
Immunoprecipitation showed that chimeric proteins could be bound by anti-tetanus antibodies in 344 
lentiviral vector suspensions. However this did not directly demonstrate that they were 345 
associated with the lentiviral envelope membrane due to the possible presence in the lentiviral 346 
preparations of exosomes and other cell debris.  In order to test this and show that binding of 347 
chimeric proteins by anti-tetanus antibodies could produce functional effects, a neutralisation 348 
assay was performed. Initially neutralising antibodies were titrated from 10 g to 200 g on 349 
LVGFP and LVTI followed by infection of HT1080 cells (data not shown).  With one batch of 350 
LVTI complete neutralisation was seen at the lowest dose while the other was maximally 351 
neutralised with a dose of 100 g and so this dose was selected for subsequent experiments. 352 
In Figure 5 HT1080 cells were separately transduced with 3 lentiviral vectors: LVTI (FLAG®-353 
TetFrC -ICAM1) whose transfer plasmid expresses surface membrane extracellular FLAG®-354 
TetFrC, LVSI (FLAG®-Streptavidin-ICAM1), a matched negative control virus where TetFrC 355 
domain is swapped for Streptavidin, and finally LVGFP, whose transfer plasmid expresses 356 
18 
cytoplasmic eGFP and would therefore not be expected to bear any surface membrane epitopes 357 
for anti-tetanus antibody neutralisation.  In parallel, HT1080 cells were transduced with lentiviral 358 
preparations that had been pre-incubated for 30 min with 100 µg anti-tetanus antibodies from 359 
human sera or in addition, for LVTI viruses, with 100 µg isotype control human IgGs.  48 h post-360 
infection, virus infectivity was assessed by measuring expression of chimeric proteins in target 361 
cells by FACS as described previously. 362 
Representative plots from each infection showing gating on positive cells are shown in 363 
Figure 5a.  Transduction by untreated LVTI and LVSI was lower than expected based on titrated 364 
MOI and the reasons for this are not yet known.  However, treatment of LVTI TetFrC Trojan 365 
viruses with human serum anti-tetanus IgG causes a dramatic reduction in transduction and this 366 
is not seen with an isotype control human IgG or when viruses were produced using either an 367 
eGFP or Streptavidin-ICAM1 expression cassette. 368 
Mean gene expression, as percentage FLAG®-positive, transduced cells, was calculated 369 
from a minimum of 3 wells for each combination of virus and antibodies and is shown in Figure 370 
5b.  Statistical analysis showed a significant (P<0.0001) decrease in transduced cells after 371 
ICAM1-TetFrC bearing viruses were treated with human serum anti-tetanus IgG but not isotype 372 
control IgG.  As expected, human serum anti-tetanus IgG pretreatment did not produce a 373 
significant effect on the mean percentage cells transduced by LVGFP or LVSI (Streptavidin-374 
ICAM1).  375 
 376 
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Discussion 378 
Altering the host cell-range of lentiviral vectors through the introduction of cell-entry glycoproteins 379 
from other enveloped viruses is a long established practice 18. In this study we have generated 380 
chimeric proteins designed to be expressed in the membrane of lentiviral vectors as they bud 381 
from host cells.  We propose these so-called Trojan proteins as a means to prevent HIV viruses 382 
from avoiding effective immune responses by making HIV virions susceptible to immunity 383 
generated by clinically proven vaccination against another pathogen such as Tetanus. The 384 
results we have shown are restricted to in vitro models with replication incompetent lentiviruses 385 
but we hypothesize that Trojan proteins could be delivered as a gene therapy in HIV infected 386 
individuals.   387 
One theoretical application for this is in so called “shock and kill” strategies, which have 388 
been proposed as a future method of sterilising cure for HIV infected patients on HAART drugs 389 
7, 28.  Small molecules are used to reactivate HIV transcription in order to expose viral reservoirs 390 
to host immune responses.  However reactivation alone has not been shown to be effective 391 
enough for patient immunity to clear the latently infected cells 7, 29.  We propose that delivery of 392 
Trojan genes to latently infected cells under the control of a Tat-responsive promoter would allow 393 
these antigens to be used during “shock and kill” therapy. We speculate that activation of HIV 394 
transcription by Latency Reversing Agents would cause cell surface expression of Trojan 395 
molecules on HIV producing cells. This would be predicted to have 2 main sequelae: firstly pre-396 
existing anti-tetanus immunity could be used to target and destroy infected cells but also any 397 
emerging HIV virus would be neutralised by serum immunity.  Future work will address the 398 
success of targeting of Trojan molecules to the surface of lab strain or patient HIV.  399 
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The Trojan expression cassette, under the control of an HIV responsive promoter, can be 400 
delivered to cells known to harbour latent HIV infection.  Delivery of gene therapy, as a strategy 401 
for HIV treatment has experienced a surge of interest after the “Berlin Patient” report showed 402 
that infusion of CCR5-negative cells could provide long-term protection from HIV re-emergence 403 
in an HIV-positive individual 30, 31.  In addition, the CRISPR/Cas9 system has been tested for 404 
HIV co-receptor knockdown to protect cells from infection but also as a means to target and 405 
destroy HIV genomes 32, 33. (Add refs Bialek and Kaminski) 406 
Clearly gene therapy strategies such as the Trojan expression we have proposed, as well 407 
as the gene editing strategies discussed above face challenges of therapeutic delivery 408 
(Saayman 2016). The cellular targets of HIV are well defined and the key reservoirs for HIV latency 409 
have been identified as resting memory T cells and cells of the myeloid lineage, with involvement of CNS 410 
cells being more controversial (reviewed in Kulpa 2015, Melkova 2016, and Joseph 2015).  Historically 411 
Lentiviral vectors have been posited as ideal vectors for treating HIV and have been shown to infect 412 
relevant target cells (Mautino 2002).  In more recent times, Lentiviral vectors have been directly tested in 413 
HIV blocking strategies using RNAi and gene editing by CRIPSR (Chung 2014, Kaminski 2016, Choi 414 
2016).  Though we have used a VSVg pseudotyped lentiviral vector expression system in our in vitro 415 
model, technologies to improve the delivery of lentiviral vectors through pseudotyping and cell-type 416 
specific retargeting are in development (Levy 2015, Kaikkonen 2009, Uhlig 2015).  Furthermore, the 417 
Trojan Chimeras genes could foreseeably be delivered by other gene therapy .vectors such as AAV, 418 
which have already been tested for use in gene editing strategies for HIV (Sather et al. 2015). 419 
With the expression of the Trojan cassette being stimulated in cells containing reactivated 420 
HIV, we predict that the newly replicated HIV released would be coated with the Tetanus antigen.  421 
Pre-treatment with anti-tetanus vaccination and passive immunisation with anti-Tetanus human 422 
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antibodies would be a way to block released virus and potentially clear the latent cellular 423 
reservoirs due to expression of Tetanus Toxoid epitopes. 424 
Initially 4 chimeric proteins were constructed and were shown to be expressed transiently 425 
on the surface of cells used for lentiviral packaging. The constructs were then used as transfer 426 
plasmids in the production of VSVg pseudo-typed lentiviral vectors.  Viral titres were variable 427 
and the titres for LVSV containing the FLAG®-Streptavidin-VSVg chimeric protein were lowest.  428 
The reasons for this trend are unknown as VSVg has been commonly used as a transmembrane 429 
carrier for lentiviral pseudo-types 18, 19.  It is possible that the chimeric VSVg transmembrane 430 
region is competing with the VSVg pseudo-type protein for recruitment to the viral surface 431 
resulting in reduced infectivity of the virus.  However, the LVTV (FLAG®-TetFrC-VSVg) titres 432 
were not significantly lower statistically than viruses carrying FLAG®-Streptavidin-ICAM1 433 
proteins. 434 
Streptavidin on the viral surface might also cause steric hindrance of virus assembly or 435 
infectivity; long cytoplasmic tails of pseudo-types from measles viruses were shown to be 436 
detrimental to lentiviral titres 34. In a study investigating the alteration of the lentiviral surface for 437 
redirection of infectivity using Streptavidin-VSVg and gp64 pseudo-types, Kaikkonen et al. 20 438 
found that ratio of pseudo-type to Streptavidin-VSVg plasmids was critical to viral titres; therefore 439 
it may be that altering the plasmid recipe may be sufficient to improve the low titres seen in our 440 
study. 441 
We also showed that Trojan lentiviral constructs could be used to transduce human cell 442 
lines and lead to surface expression of TetFrC antigen.  In the absence of selection, in both cell 443 
types and with both viruses there was TetFrC surface-expression in a subset of cells at two 444 
months post-transfection, though longer term expression was not tested.  A broad range of MFI 445 
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was seen particularly in the 293T wells but was not unexpected given the adherent nature of the 446 
cells and the dilution method used. 447 
Transduced PM1 wells at two months post-infection showed a narrow peak of expression 448 
but also contained some dim and FLAG®-negative cells; a gradual loss of expression of chimeric 449 
antigens from daughter cells cannot be excluded.  Further sorting and screening may identify 450 
true stable clones with more restricted ranges of MFI. 451 
The 293T lines so generated have the potential to be used as cell factories for further 452 
production of the Trojan-altered viruses, for example with eGFP transgene cassettes. PM1 T cell 453 
lines express the CD4 receptor and co-receptors CCR5 and CXCR4  necessary for infection by 454 
macrophage and T cell trophic (R5 and X4) strains of HIV.  PM1 T cells expressing the Trojan 455 
antigen can be used to test whether HIV lab strains or primary isolates would be coated with 456 
TetFrC protein and therefore be neutralised by anti-Tetanus antibodies 35. Such T cell lines can 457 
also be used to test the potential for HIV mutational escape from the Trojan strategy 32. 458 
The key to generating effective antibodies against HIV envelope protein by vaccination 459 
remains elusive. Our results have demonstrated that other immunogenic proteins can be 460 
delivered to the surface envelope of lentiviruses and that this can make them susceptible to 461 
neutralisation by antibodies against a different pathogen.  In figure 5 we used the equivalent of 462 
2.3 IU/mL of international standard human tetanus immunoglobulin for neutralisation; units in 463 
this antibody are based on in vivo neutralisation assays in mice.  However, some batches of 464 
Trojan virus were completely neutralised with 10 fold less antibody (data not shown).  Different 465 
amounts of debris in lentiviral vectors prepared by ultracentrifugation without density cushions 466 
may be a possible cause of this experimental variation. 0.01 IU/mL is considered to be protective 467 
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against tetanus infection in human sera 36.  The concentration of antibody needed to neutralise 468 
HIV in the context of our proposed Trojan therapy would require further analysis.  469 
The effect on lentiviral titres and stability of altering the viral envelope in this way requires 470 
further investigation since we noted lower transduction than predicted based on original titration, 471 
in particular with LVSI, in our neutralisation studies.  Some error may be inherent to the titration 472 
method used but it is possible that alteration of the envelope may have consequences for the 473 
stability of viral vectors during storage and thawing. 474 
We have demonstrated that Lentiviral vector mediated delivery can be used to deliver 475 
Trojan proteins for expression on the surface of the T cell line PM1.  Clearly, the effectiveness 476 
of lentiviral Trojan delivery to primary patient T cells requires testing.  Uncontrolled expression 477 
of Trojan proteins on T cells may be undesirable but lysis of non-HIV-infected cells due to anti-478 
Trojan immunity has the potential to be controlled by making Trojan protein expression 479 
dependent on HIV transcription 37, 38.  Testing Trojan protein expression in T cell lines may also 480 
reveal whether, in addition to neutralising cell-free virus, antigen expression on the host cell 481 
surface may cause anti-host cell immune responses against Tetanus epitopes. 482 
To our knowledge, diverting neutralising immunity against one pathogen onto another is an 483 
entirely novel concept at this time, though suicide gene therapies have been suggested for HIV 484 
and other diseases.  For example, the conditional expression of a thymidine kinase in T cells 485 
has recently been reported to cause cytotoxicity upon ganciclovir treatment in HIV infected cells 486 
and a similar gene therapy using thymidine kinase induced drug sensitivity has been tested for 487 
prostate cancer 39, 40.  In our experiments we have used TetFrC as a model antigen with known 488 
human serum neutralising antibodies but it may be possible and desirable to use other or 489 
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perhaps multiple antigens to reduce the potential for mutational escape and/or reductions in 490 
responses due to HIV-mediated damage to immune responses 41, 42. 491 
In addition, the ability to display such Trojan proteins on the lentiviral envelope has other 492 
possible applications for pseudo-typing of lentiviral vectors.  For example, a modified TetFrC has 493 
been proposed for use to direct neurotropism of viral vectors 43. Furthermore, ICAM1 as a 494 
transmembrane anchor may offer new ways targeting lentiviral vectors to specific cell types. Our 495 
expression cassette design offers the possibility for interchangeability of transmembrane and 496 
extracellular domains. 497 
 498 
Conclusions 499 
We have generated novel chimeric proteins designed to coat lentiviruses with antigens from 500 
other pathogens to which neutralising memory immunity is present in vaccinated human 501 
populations.   We predict that altering HIV particle surface will redirect these immune responses 502 
to neutralise HIV. Overall, the foundation data in this paper show that the Trojan chimeric 503 
molecules for neutralisation of lentiviral particles are functional and merit further investigation. 504 
 505 
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1 
Figure Legends 1 
 2 
Fig. 1. Schematic structure of lentiviral vector and chimeric constructs. Top diagram shows 3 
the lentiviral eGFP transgene transfer vector pRRLsc_CEW used for control lentivirus production 4 
in this study. Domain structure of chimeric transgenes   TI, SI, TV and SV. The TI and SI 5 
constructs consist of a gp64 signal peptide (light grey rectangle, 21 amino acids (aa)), followed 6 
by FLAG®-epitope (black rectangle, 9 aa) tagged TetFrC (451 aa) or Streptavidin (StrAv, 159 7 
aa) extracellular domain fused to the Transmembrane and Cytoplasmic domains (T/C) of VSVg 8 
(dark grey rectangle, 72 aa). In the TV and SV constructs FLAG- tagged TetFrC or Streptavidin 9 
extracellular domains are fused to ICAM1 signal peptide (light grey striped rectangle, 26 aa) and 10 
T/C (black striped rectangle, 64 aa). 11 
 12 
Fig. 2. Transient transfection of lentiviral vector plasmids carrying Trojan constructs. (a) 13 
Lentiviral Transfer plasmids TI, SI, TV and SV were transiently transfected into 293T cells using 14 
Lipofectamine®. On d3 post-transfection cells were stained with isotype control (mIgG1, grey fill 15 
plot), anti-FLAG® (black line) or anti-TetFrC (dashed line) antibodies followed by secondary 16 
antibody conjugated to Alexa Fluor® 647 and analysed by FACS. (b) Expression levels of 17 
chimeric proteins above background from mock transfected cells stained in the same way were 18 
quantified 48 h post-transfection of 293T cells using Calcium Phosphate (n=3 per plasmid). 19 
Representative FACS histograms are shown. Chart shows mean of 3 wells for % positive cells 20 
above background (black bars) and Median Fluorescence Intensity (MFI, grey bars). Error bars 21 
are ± SD of the mean. Lines with asterisks indicate significant differences between means (* P 22 
≤ 0.05, ** P ≤ 0.01 and *** P ≤ 0.001). 23 
2 
 24 
Fig. 3. Gene expression from cells infected by lentiviruses bearing chimeric transfer 25 
cassettes. (a and c) 293T cells (b and d) PM1 T cells were infected with LVTI and LVSI. On day 26 
3 post-infection untransduced (grey fill) or transduced (black line) cells were stained with anti-27 
FLAG® antibody and fluorescent-conjugated secondary and analysed by FACS. After dilution 28 
cloning and growth, 293T (c) and PM1 (d) cell colonies were stained with anti-FLAG® antibody 29 
and secondary antibody followed by FACS. Percentages are FLAG positive cells above 30 
background. PM1 colonies SI.6 and TI.20 were further analysed for median fluorescence 31 
intensity of FLAG positive cells (lower value). 32 
 33 
Fig. 4. Immunoprecipitation of chimeric proteins in lentiviral preparations with human 34 
anti-Tetanus antibodies. Lentiviral preparations made using chimeric transfer cassettes were 35 
left unprecipitated (U, lane 1), immunoprecipitated with negative control human IgG (hIgG, lane 36 
4) or human anti-tetanus IgG (hTetIgG, lane 5). For molecular weight controls, lysates were 37 
prepared from 293T cells transfected with chimeric constructs and cell lysates were 38 
immunoprecipitated with negative control human IgG (hIgG, lane 2) or human anti-tetanus IgG 39 
(hTetIgG, lane 3). PGNase F treated lysates and immunoprecipitates were separated by SDS-40 
PAGE and western blots were probed with M2-HRP antibody. 41 
 42 
Fig. 5. The effect of anti-Tetanus antibodies on lentiviruses bearing Trojan chimeric 43 
proteins.  Lentiviruses were pretreated with PBS, isotype control hIgG antibody or anti-Tetanus 44 
serum polyclonal IgG antibody. HT1080 cells were then infected for 18h before virus was 45 
removed. 48h post-infection cells were analysed by FACS for expression of surface FLAG® 46 
3 
epitope. (a) Representative FACS plots with percentage positive cells above background given 47 
in top right corner.   (b) Mean % transduced cells above background was calculated. Lentivirus 48 
was left untreated (PBS, black columns), or pretreated with human anti-Tetanus serum 49 
polyclonal IgG antibody (white columns), or with isotype control hIgG antibody (grey column). 50 
Error bars are ± SD of the mean. Lines with asterisks indicate significant differences between 51 




Table 1: Titre Transducing Units/mL in HT1080 cells 
LVGFP LVTV LVTI LVSV LVSI 
1.20E+09 1.10E+07 7.10E+07 1.83E+05 6.60E+06 
1.60E+08 4.20E+07 9.80E+08 2.40E+06 5.00E+06 
6.30E+08 2.26E+06 5.70E+07 Not detected 2.40E+06 
2.50E+08 1.32E+06 3.78E+07   
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